Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-085 Long-term Study in Hypertriglyceridemia
NCT01350999Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (3 arms), sponsored by Takeda. Primary endpoint: Treatment Emergent Adverse Events at 52 weeks. Started Nov 2009; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01350999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350999.